Featured Research

from universities, journals, and other organizations

H9N2 Avian Flu Vaccine Paired With Adjuvant Provokes Strong Human Immune Response At Low Doses

Date:
September 26, 2006
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
When combined with an immune-boosting substance called an adjuvant, low doses of an experimental vaccine against a strain of avian influenza (H9N2) provoked a strong antibody response in human volunteers, report scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

When combined with an immune-boosting substance called an adjuvant, low doses of an experimental vaccine against a strain of avian influenza (H9N2) provoked a strong antibody response in human volunteers, report scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The clinical trial of 96 adults was conducted at the NIAID-supported Viral Respiratory Pathogens Research Unit at Baylor College of Medicine, Houston, and was led by Robert L. Atmar, M.D. The results are now online in Clinical Infectious Diseases.

"The results of this clinical trial add to the growing body of information demonstrating the potential value of adjuvanted avian influenza vaccines," says NIAID Director Anthony S. Fauci, M.D. An adjuvant is a substance that is added to a vaccine to boost the body's immune response to the vaccine's antigen. "In the event of an influenza pandemic, adjuvanted vaccines could provide a way to extend a limited vaccine supply to more people," he adds.

In 1999, two children in Hong Kong became infected with H9N2, a strain of avian influenza that had not previously been detected in humans. Humans have little or no natural immunity to a virus--such as H9N2 or the more deadly H5N1 avian influenza--that historically has circulated only in birds. If H9N2 or H5N1 were to acquire the ability to spread easily from person to person, an influenza pandemic could result, health experts say.

In 2004, NIAID directed Novartis Vaccines and Diagnostics (formerly Chiron Corporation) to produce 40,000 doses of an experimental H9N2 vaccine at its vaccine manufacturing facility in Siena, Italy. Some of the vaccines were formulated with Novartis's MF59 adjuvant.

Dr. Atmar and his colleagues tested the vaccines in volunteers aged 18 to 34 in this Phase I clinical trial. Phase I vaccine trials assess candidate vaccines' safety and ability to stimulate an immune system response, and are not designed to determine whether the vaccine would prevent infection by naturally occurring virus. The researchers vaccinated 48 volunteers with non-adjuvanted H9N2 vaccine (made from inactivated virus) at one of four dosages--3.75, 7.5, 15 or 30 micrograms. An additional 48 volunteers received MF59-adjuvanted vaccine at one of the same four dosages. Volunteers were vaccinated twice, with inoculations spaced 28 days apart.

An avian flu vaccine, like the seasonal flu vaccine, should stimulate antibodies, which help ward off infection if the vaccinated person later encounters the flu virus. In general, the higher the level of antibodies made in response to a vaccine, the more protective the vaccine is, Dr. Atmar notes.

"In our trial, a single inoculation of adjuvant-containing H9N2 vaccine, even at the lowest dosage, generated a good antibody response," says Dr. Atmar. By comparison, the seasonal flu vaccine contains 15 micrograms each of three different circulating flu strains--much higher than the 3.75 micrograms of H9N2 flu virus contained in the lowest dose vaccine tested in this trial. Furthermore, he adds, a single dose of the adjuvanted H9N2 vaccine was as good as two doses of the vaccine without adjuvant.

Currently, MF59 is licensed for use as a vaccine adjuvant in Europe but not in the United States. The results of this trial, says Dr. Atmar, suggest that MF59 is deserving of further study.

For more information on influenza see http://www3.niaid.nih.gov/news/focuson/flu. Also visit http://www.PandemicFlu.gov for one-stop access to U.S. Government information on avian and pandemic flu.

NIAID is a component of the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies.


Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "H9N2 Avian Flu Vaccine Paired With Adjuvant Provokes Strong Human Immune Response At Low Doses." ScienceDaily. ScienceDaily, 26 September 2006. <www.sciencedaily.com/releases/2006/09/060925162557.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2006, September 26). H9N2 Avian Flu Vaccine Paired With Adjuvant Provokes Strong Human Immune Response At Low Doses. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2006/09/060925162557.htm
NIH/National Institute of Allergy and Infectious Diseases. "H9N2 Avian Flu Vaccine Paired With Adjuvant Provokes Strong Human Immune Response At Low Doses." ScienceDaily. www.sciencedaily.com/releases/2006/09/060925162557.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Costs Keep Mounting

Ebola Costs Keep Mounting

Reuters - Business Video Online (Sep. 23, 2014) The WHO has warned up to 20,000 people could be infected with Ebola over the next few weeks. As Sonia Legg reports, the implications for the West African countries suffering from the disease are huge. Video provided by Reuters
Powered by NewsLook.com
Ebola Cases Could Reach 1.4 Million Within 4 Months

Ebola Cases Could Reach 1.4 Million Within 4 Months

Newsy (Sep. 23, 2014) Health officials warn that without further intervention, the number of Ebola cases in Liberia and Sierra Leone could reach 1.4 million by January. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Cases to Triple in Weeks Without Drastic Action

WHO: Ebola Cases to Triple in Weeks Without Drastic Action

AFP (Sep. 23, 2014) The number of Ebola infections will triple to 20,000 by November, soaring by thousands every week if efforts to stop the outbreak are not stepped up radically, the WHO warned in a study on Tuesday. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
5 Ways Men Can Prevent Most Heart Attacks

5 Ways Men Can Prevent Most Heart Attacks

Newsy (Sep. 23, 2014) No surprise here: A recent study says men can reduce their risk of heart attack by maintaining a healthy lifestyle, which includes daily exercise. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins